Drug Profile

Gene editing therapeutic - Prime Medicine

Latest Information Update: 31 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Prime Medicine
Class Gene therapies
Mechanism of Action

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Alpha 1-antitrypsin deficiency

Most Recent Events

18 Mar 2025 Preclinical trials in Alpha 1-antitrypsin deficiency in USA (Parenteral) prior to March 2025
18 Mar 2025 Prime Medicine announces intention to submit an investigational new drug (IND) and/or clinical trial application (CTA) for Alpha-1 antitrypsin deficiency in mid-2026
18 Mar 2025 Pharmacodynamics data from a preclinical study in Alpha-1 antitrypsin deficiency released by Prime Medicine

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com